These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 29957018

  • 1. Salubrinal Enhances Doxorubicin Sensitivity in Human Cholangiocarcinoma Cells Through Promoting DNA Damage.
    Yu W, Xiang Y, Luo G, Zhao X, Xiao B, Cheng Y, Feng C, Duan C, Xia X, Wong VKW, Dai R.
    Cancer Biother Radiopharm; 2018 Aug; 33(6):258-265. PubMed ID: 29957018
    [Abstract] [Full Text] [Related]

  • 2. Synergistic antitumor activity of the combination of salubrinal and rapamycin against human cholangiocarcinoma cells.
    Zhao X, Zhang C, Zhou H, Xiao B, Cheng Y, Wang J, Yao F, Duan C, Chen R, Liu Y, Feng C, Li H, Li J, Dai R.
    Oncotarget; 2016 Dec 20; 7(51):85492-85501. PubMed ID: 27863431
    [Abstract] [Full Text] [Related]

  • 3. Activated Integrated Stress Response Induced by Salubrinal Promotes Cisplatin Resistance in Human Gastric Cancer Cells via Enhanced xCT Expression and Glutathione Biosynthesis.
    Wang SF, Wung CH, Chen MS, Chen CF, Yin PH, Yeh TS, Chang YL, Chou YC, Hung HH, Lee HC.
    Int J Mol Sci; 2018 Oct 29; 19(11):. PubMed ID: 30380689
    [Abstract] [Full Text] [Related]

  • 4. Salubrinal-Mediated Upregulation of eIF2α Phosphorylation Increases Doxorubicin Sensitivity in MCF-7/ADR Cells.
    Jeon YJ, Kim JH, Shin JI, Jeong M, Cho J, Lee K.
    Mol Cells; 2016 Feb 29; 39(2):129-35. PubMed ID: 26743901
    [Abstract] [Full Text] [Related]

  • 5. Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines.
    Tepsiri N, Chaturat L, Sripa B, Namwat W, Wongkham S, Bhudhisawasdi V, Tassaneeyakul W.
    World J Gastroenterol; 2005 May 14; 11(18):2748-53. PubMed ID: 15884115
    [Abstract] [Full Text] [Related]

  • 6. Melatonin induces apoptosis in cholangiocarcinoma cell lines by activating the reactive oxygen species-mediated mitochondrial pathway.
    Laothong U, Hiraku Y, Oikawa S, Intuyod K, Murata M, Pinlaor S.
    Oncol Rep; 2015 Mar 14; 33(3):1443-9. PubMed ID: 25606968
    [Abstract] [Full Text] [Related]

  • 7. Knockdown of cullin 3 inhibits progressive phenotypes and increases chemosensitivity in cholangiocarcinoma cells.
    Pratummanee K, Kerdkumthong K, Roytrakul S, Tantimetta P, Runsaeng P, Saeheng S, Obchoei S.
    Mol Med Rep; 2024 Nov 14; 30(5):. PubMed ID: 39239747
    [Abstract] [Full Text] [Related]

  • 8. Effect of β-Eudesmol on NQO1 suppression-enhanced sensitivity of cholangiocarcinoma cells to chemotherapeutic agents.
    Srijiwangsa P, Ponnikorn S, Na-Bangchang K.
    BMC Pharmacol Toxicol; 2018 Jun 19; 19(1):32. PubMed ID: 29914576
    [Abstract] [Full Text] [Related]

  • 9. Curcumin analog WZ26 induces ROS and cell death via inhibition of STAT3 in cholangiocarcinoma.
    Chen M, Qian C, Jin B, Hu C, Zhang L, Wang M, Zhou B, Zuo W, Huang L, Wang Y.
    Cancer Biol Ther; 2023 Dec 31; 24(1):2162807. PubMed ID: 36647192
    [Abstract] [Full Text] [Related]

  • 10. Amplified in breast cancer 1 enhances human cholangiocarcinoma growth and chemoresistance by simultaneous activation of Akt and Nrf2 pathways.
    Chen Q, Li W, Wan Y, Xia X, Wu Q, Chen Y, Lai Z, Yu C, Li W.
    Hepatology; 2012 Jun 31; 55(6):1820-9. PubMed ID: 22213475
    [Abstract] [Full Text] [Related]

  • 11. Blocking of methionine aminopeptidase-2 by TNP-470 induces apoptosis and increases chemosensitivity of cholangiocarcinoma.
    Kidoikhammouan S, Seubwai W, Silsirivanit A, Wongkham S, Sawanyawisuth K, Wongkham C.
    J Cancer Res Ther; 2019 Jun 31; 15(1):148-152. PubMed ID: 30880771
    [Abstract] [Full Text] [Related]

  • 12. Mycoepoxydiene induces apoptosis and inhibits TPA-induced invasion in human cholangiocarcinoma cells via blocking NF-κB pathway.
    Li W, Li M, Su X, Qin L, Miao M, Yu C, Shen Y, Luo Q, Chen Q.
    Biochimie; 2014 Jun 31; 101():183-91. PubMed ID: 24486723
    [Abstract] [Full Text] [Related]

  • 13. The H4 histamine receptor agonist, clobenpropit, suppresses human cholangiocarcinoma progression by disruption of epithelial mesenchymal transition and tumor metastasis.
    Meng F, Han Y, Staloch D, Francis T, Stokes A, Francis H.
    Hepatology; 2011 Nov 31; 54(5):1718-28. PubMed ID: 21793031
    [Abstract] [Full Text] [Related]

  • 14. TRAIL Enhances Shikonin Induced Apoptosis through ROS/JNK Signaling in Cholangiocarcinoma Cells.
    Zhou G, Yang Z, Wang X, Tao R, Zhou Y.
    Cell Physiol Biochem; 2017 Nov 31; 42(3):1073-1086. PubMed ID: 28662515
    [Abstract] [Full Text] [Related]

  • 15. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
    Ewald F, Grabinski N, Grottke A, Windhorst S, Nörz D, Carstensen L, Staufer K, Hofmann BT, Diehl F, David K, Schumacher U, Nashan B, Jücker M.
    Int J Cancer; 2013 Nov 31; 133(9):2065-76. PubMed ID: 23588885
    [Abstract] [Full Text] [Related]

  • 16. Upregulation of retinoic acid receptor-β reverses drug resistance in cholangiocarcinoma cells by enhancing susceptibility to apoptosis.
    Ren HY, Chen B, Huang GL, Liu Y, Shen DY.
    Mol Med Rep; 2016 Oct 31; 14(4):3602-8. PubMed ID: 27599527
    [Abstract] [Full Text] [Related]

  • 17. Targeting the ∆133p53 isoform can restore chemosensitivity in 5-fluorouracil-resistant cholangiocarcinoma cells.
    Nutthasirikul N, Hahnvajanawong C, Techasen A, Limpaiboon T, Leelayuwat C, Chau-In S, Jearanaikoon P.
    Int J Oncol; 2015 Dec 31; 47(6):2153-64. PubMed ID: 26459801
    [Abstract] [Full Text] [Related]

  • 18. Lovastatin overcomes gefitinib resistance through TNF-α signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo.
    Yang SH, Lin HY, Chang VH, Chen CC, Liu YR, Wang J, Zhang K, Jiang X, Yen Y.
    Oncotarget; 2015 Sep 15; 6(27):23857-73. PubMed ID: 26160843
    [Abstract] [Full Text] [Related]

  • 19. A Runaway PRH/HHEX-Notch3-Positive Feedback Loop Drives Cholangiocarcinoma and Determines Response to CDK4/6 Inhibition.
    Kitchen P, Lee KY, Clark D, Lau N, Lertsuwan J, Sawasdichai A, Satayavivad J, Oltean S, Afford S, Gaston K, Jayaraman PS.
    Cancer Res; 2020 Feb 15; 80(4):757-770. PubMed ID: 31843982
    [Abstract] [Full Text] [Related]

  • 20. Eukaryotic initiation factor 2α--a downstream effector of mammalian target of rapamycin--modulates DNA repair and cancer response to treatment.
    Tuval-Kochen L, Paglin S, Keshet G, Lerenthal Y, Nakar C, Golani T, Toren A, Yahalom J, Pfeffer R, Lawrence Y.
    PLoS One; 2013 Feb 15; 8(10):e77260. PubMed ID: 24204783
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.